S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Is AMC Entertainment Pulling a Fast One on the APEs?
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Boredom, loneliness plague Ukrainian youth near front line
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
High oil prices help Saudi Aramco earn $88B in first half
How Much Longer Will It Be Under $1? (Ad)pixel
Ship carrying grain for hungry Ethiopia leaves Ukraine
Here’s How the Inflation Reduction Act Energizes Power Stock
Average US gasoline price falls 45 cents to $4.10 per gallon
How Much Longer Will It Be Under $1? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Is AMC Entertainment Pulling a Fast One on the APEs?
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Boredom, loneliness plague Ukrainian youth near front line
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
High oil prices help Saudi Aramco earn $88B in first half
How Much Longer Will It Be Under $1? (Ad)pixel
Ship carrying grain for hungry Ethiopia leaves Ukraine
Here’s How the Inflation Reduction Act Energizes Power Stock
Average US gasoline price falls 45 cents to $4.10 per gallon
How Much Longer Will It Be Under $1? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Is AMC Entertainment Pulling a Fast One on the APEs?
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Boredom, loneliness plague Ukrainian youth near front line
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
High oil prices help Saudi Aramco earn $88B in first half
How Much Longer Will It Be Under $1? (Ad)pixel
Ship carrying grain for hungry Ethiopia leaves Ukraine
Here’s How the Inflation Reduction Act Energizes Power Stock
Average US gasoline price falls 45 cents to $4.10 per gallon
How Much Longer Will It Be Under $1? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Is AMC Entertainment Pulling a Fast One on the APEs?
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Boredom, loneliness plague Ukrainian youth near front line
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
High oil prices help Saudi Aramco earn $88B in first half
How Much Longer Will It Be Under $1? (Ad)pixel
Ship carrying grain for hungry Ethiopia leaves Ukraine
Here’s How the Inflation Reduction Act Energizes Power Stock
Average US gasoline price falls 45 cents to $4.10 per gallon
How Much Longer Will It Be Under $1? (Ad)pixel
NASDAQ:BLUE

bluebird bio - BLUE Stock Forecast, Price & News

$6.72
+0.41 (+6.50%)
(As of 08/12/2022 09:14 PM ET)
Add
Compare
Today's Range
$6.33
$7.00
50-Day Range
$2.98
$6.72
52-Week Range
$2.87
$25.39
Volume
7.36 million shs
Average Volume
4.71 million shs
Market Capitalization
$518.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.09

bluebird bio MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
50.2% Upside
$10.09 Price Target
Short Interest
Healthy
19.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.68mentions of bluebird bio in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$146,664 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.81) to ($2.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

766th out of 1,135 stocks

Biological Products, Except Diagnostic Industry

119th out of 180 stocks

BLUE stock logo

About bluebird bio (NASDAQ:BLUE) Stock

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

bluebird bio Stock Performance

Shares of NASDAQ:BLUE traded up $0.41 during trading hours on Friday, reaching $6.72. The stock had a trading volume of 7,359,542 shares, compared to its average volume of 6,021,368. bluebird bio has a 1 year low of $2.87 and a 1 year high of $25.39. The firm's 50 day moving average is $4.52 and its 200-day moving average is $4.71. The stock has a market capitalization of $518.25 million, a price-to-earnings ratio of -0.81 and a beta of 1.29.

bluebird bio (NASDAQ:BLUE - Get Rating) last announced its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($1.29) EPS for the quarter, beating analysts' consensus estimates of ($1.31) by $0.02. bluebird bio had a negative net margin of 2,141.34% and a negative return on equity of 130.19%. The company had revenue of $1.52 million for the quarter, compared to the consensus estimate of $6.47 million. Analysts forecast that bluebird bio will post -4.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Morgan Stanley cut their target price on shares of bluebird bio to $3.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 17th. Raymond James raised shares of bluebird bio from a "market perform" rating to an "outperform" rating and set a $8.00 target price on the stock in a research note on Tuesday, August 2nd. Wedbush cut their target price on shares of bluebird bio from $10.00 to $8.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 10th. Finally, Barclays raised shares of bluebird bio from an "underweight" rating to an "equal weight" rating and upped their target price for the stock from $3.00 to $5.00 in a research note on Friday, August 5th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $10.50.

Insider Activity

In other news, CEO Andrew Obenshain sold 21,805 shares of the company's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total value of $95,723.95. Following the completion of the transaction, the chief executive officer now owns 247,131 shares in the company, valued at approximately $1,084,905.09. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, insider Jason Cole sold 7,448 shares of the company's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total value of $32,696.72. Following the completion of the transaction, the insider now owns 203,740 shares in the company, valued at approximately $894,418.60. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Andrew Obenshain sold 21,805 shares of the company's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total transaction of $95,723.95. Following the completion of the transaction, the chief executive officer now owns 247,131 shares of the company's stock, valued at approximately $1,084,905.09. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,364 shares of company stock worth $146,664. Corporate insiders own 2.90% of the company's stock.

Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

BLUE Stock News Headlines

Barclays Upgrades bluebird bio (NASDAQ:BLUE) to "Equal Weight"
Why Bluebird Bio Stock Is Flying Today
Is Now a Good Time to Buy This Biotech Stock?
Why Bluebird Bio Stock Stumbled Today
bluebird bio (Finally) Nears Approval. What's Next?
See More Headlines
Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

BLUE Company Calendar

Last Earnings
8/04/2022
Today
8/15/2022
Next Earnings (Estimated)
11/04/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLUE
Fax
N/A
Employees
518
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.09
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+50.2%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
12 Analysts

Profitability

Net Income
$-819,380,000.00
Net Margins
-2,141.34%
Pretax Margin
-1,828.94%

Debt

Sales & Book Value

Annual Sales
$3.66 million
Book Value
$5.34 per share

Miscellaneous

Free Float
74,885,000
Market Cap
$518.26 million
Optionable
Optionable
Beta
1.29

Key Executives














BLUE Stock - Frequently Asked Questions

Should I buy or sell bluebird bio stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 1 sell rating, 8 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings
or view top-rated stocks.

What is bluebird bio's stock price forecast for 2022?

12 Wall Street analysts have issued 12-month price targets for bluebird bio's shares. Their BLUE share price forecasts range from $3.00 to $23.00. On average, they anticipate the company's share price to reach $10.09 in the next twelve months. This suggests a possible upside of 50.2% from the stock's current price.
View analysts price targets for BLUE
or view top-rated stocks among Wall Street analysts.

How have BLUE shares performed in 2022?

bluebird bio's stock was trading at $9.99 at the beginning of 2022. Since then, BLUE stock has decreased by 32.7% and is now trading at $6.72.
View the best growth stocks for 2022 here
.

When is bluebird bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our BLUE earnings forecast
.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) posted its quarterly earnings results on Thursday, August, 4th. The biotechnology company reported ($1.29) earnings per share for the quarter, beating the consensus estimate of ($1.31) by $0.02. The biotechnology company earned $1.52 million during the quarter, compared to analyst estimates of $6.47 million. bluebird bio had a negative trailing twelve-month return on equity of 130.19% and a negative net margin of 2,141.34%.

What is Nick Leschly's approval rating as bluebird bio's CEO?

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.64%), JPMorgan Chase & Co. (2.21%), Credit Suisse AG (2.08%), Pictet Asset Management SA (0.92%), Northern Trust Corp (0.82%) and Mirae Asset Global Investments Co. Ltd. (0.44%). Insiders that own company stock include Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, David Davidson, Jason Cole, Jeffrey T Walsh, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Philip D Gregory, Thomas J Klima and William D Baird III.
View institutional ownership trends
.

How do I buy shares of bluebird bio?

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $6.72.

How much money does bluebird bio make?

bluebird bio (NASDAQ:BLUE) has a market capitalization of $518.26 million and generates $3.66 million in revenue each year. The biotechnology company earns $-819,380,000.00 in net income (profit) each year or ($8.32) on an earnings per share basis.

How many employees does bluebird bio have?

The company employs 518 workers across the globe.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com.

This page (NASDAQ:BLUE) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.